Introduction and Objective: The persistence of a high cardiovascular risk not dependent on LDL-C levels constitutes the residual cardiovascular risk of lipid origin (RLR). Lipid-lowering treatment does not always consider the modification of RLR. The present study aimed to evaluate the changes in RRL profile in patients with T2D and dyslipidemia treated with a fixed-dose combination (FDC) of Atorvastatin/Fenofibrate.

Methods: A phase IIIb, randomized, prospective, double-blind, multicenter study in the Mexican population with diagnosis of T2D and mixed dyslipidemia. Patients were randomized to the Atorvastatin/Fenofibrate 20 mg/160 mg or Atorvastatin 20 mg once daily for four months. As part of the RLR evaluation, Triglycerides/HDL-C, residual cholesterol, Total cholesterol/HDL-C, and the triglycerides-to-glucose index (TyG) were estimated. Student's t-test and McNemar test (differences within groups) χ2, and independent samples Student's t-test were applied.

Results: We included 65 patients with an average age of 56.8 ± 10.4 years. After two months of follow-up, there was a triglycerides reduction of -132.7 ± 145.3 mg/dL in the FDC group and of -68.7 ± 75.7 mg/dL with Atorvastatin therapy, while for the fourth month, the reduction was -138.3 ± 123.7 mg/dL and -60.5 ± 80.1 mg/dL, respectively. When evaluating RLR, both groups experienced a reduction in this profile, after 2 and 4 months of evaluation. However, when comparing the mean change reductions between groups of Triglycerides/HDL-C ratio (-3.9 vs -1.3, p=0.020), residual cholesterol (-19 vs -9.4, p= 0.018), and TyG (-0.7 vs -0.2, p=0.002) a superior outcome was found in FDC compared with the monotherapy group.

Conclusions: Patients receiving Atorvastatin/Fenofibrate FDC had a better reduction than monotherapy in non-LDL cholesterol-dependent RRL markers, which translates to a decrease in overall cardiovascular risk for this treatment group.

Disclosure

J.G. Sander-Padilla: Employee; Laboratorios Silanes. L.A. Lugo-Sánchez: Employee; Laboratorios Silanes S.A. de C.V. K.F. Rios-Brito: Employee; Laboratorios Silanes S.A. de C.V. K.E. Rodriguez-Rocandio: Employee; Laboratorios Silanes S.A. de C.V. M.M. Arguedas: Employee; Laboratorios Silanes S.A. de C.V. D. Flores-Huanosta: Employee; Laboratorios Silanes. I.C. Rodriguez-Vazquez: Employee; Laboratorios Silanes S.A. de C.V. J. Gonzalez-Canudas: Employee; Silanes SA CV. Y. Romero: Employee; Laboratorios Silanes.

Funding

Laboratorios Silanes

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.